Qi-Feng Liu

Qi-Feng Liu

Auto-generated profile, based on publicly available information

Qi-Feng Liu

Department of Nephrology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, 215300, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Metabolism
Verified
Journal Article
Open access
SLSha-Sha Li
Sha-Sha Li
MSMing-Jie Sheng
Ming-Jie Sheng
ZSZhuo-Yi Sun
Zhuo-Yi Sun
YLYan Liang
Yan Liang
LYLi-Xia Yu
Li-Xia Yu
QLQi-Feng Liu
Qi-Feng Liu
Klotho is a critical protein that protects the kidney. Klotho is severely downregulated in chronic kidney disease (CKD), and its deficiency is implicated in the pathogenesis and progression of CKD. Conversely, an increase in Klotho levels results in improved kidney function and delays CKD progression, supporting the notion that modulating Klotho levels could represent a possible therapeutic strategy for CKD treatment. Nevertheless, the regulatory mechanisms responsible for the loss of Klotho remain elusive. Previous studies have demonstrated that oxidative stress, inflammation, and epigenetic modifications can modulate Klotho levels. These mechanisms result in a decrease in Klotho mRNA transcript levels and reduced translation, thus can be grouped together as upstream regulatory mechanisms. However, therapeutic strategies that aim to rescue Klotho levels by targeting these upstream mechanisms do not always result in increased Klotho, indicating the involvement of other regulatory mechanisms. Emerging evidence has shown that endoplasmic reticulum (ER) stress, the unfolded protein response, and ER-associated degradation also affect the modification, translocation, and degradation of Klotho, and thus are proposed to be downstream regulatory mechanisms. Here, we discuss the current understanding of upstream and downstream regulatory mechanisms of Klotho and examine potential therapeutic strategies to upregulate Klotho expression for CKD treatment.

5 April 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SLShasha Li
Shasha Li
LYLixia Yu
Lixia Yu
AHAolin He
Aolin He
QLQifeng Liu
Qifeng Liu
This study aimed to evaluate repression of Klotho on unilateral ureteral obstruction (UUO)-induced renal fibrosis and endothelial-to-mesenchymal transition (EndoMT) in mice. Renal fibrosis model was established by UUO in C57BL/6 male mice. Recombinant Klotho protein was administered to UUO mice as treatment group, and the mice in sham and UUO group were administered with an equal volume of vehicle. EndoMT biomarkers and TGF-β1/Smad2/Snail1 signaling were examined by immunofluorescence, immunohistochemistry, and western blotting assays. UUO deteriorated kidney function and resulted in increased expression of the mesenchymal marker α-smooth muscle actin and decreased expression of vascular endothelial cadherin, an endothelial marker. Moreover, UUO enhanced TGF-β1, phosphorylated Smad2 (p-Smad2), and Snail1 expression. Interestingly, Klotho treatment suppressed UUO-induced TGF-β1, p-Smad3, and Snail1 expression, which was accompanied by alleviation of the EndoMT process. Our findings demonstrated that Klotho significantly ameliorated EndoMT progression by targeting TGF-β1/Smad/Snail1 signaling in UUO mice, which provides the possibility for Klotho-based therapeutic protection against renal fibrosis.

21 September 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
LYLi-Xia Yu
Li-Xia Yu
SLSha-Sha Li
Sha-Sha Li
MSMin-Yue Sha
Min-Yue Sha
JKJia-Wei Kong
Jia-Wei Kong
JYJian-Ming Ye
Jian-Ming Ye
QLQi-Feng Liu
Qi-Feng Liu
Klotho is an identified longevity gene with beneficial pleiotropic effects on the kidney. Evidence shows that a decline in serum Klotho level occurs in early chronic kidney disease (CKD) and continues as CKD progresses. Klotho deficiency is associated with poor clinical outcomes and CKD mineral bone disorders (CKD-MBD). Klotho has been postulated as a candidate biomarker in the evaluation of CKD. However, the evidence for the clinical significance of the relationship between Klotho and kidney function, CKD stage, adverse kidney and/or non-kidney outcomes, and CKD-MBD remains inconsistent and in some areas, contradictory. Therefore, there is uncertainty as to whether Klotho is a potential biomarker in CKD; a general consensus regarding the clinical significance of Klotho in CKD has not been reached, and there is limited evidence synthesis in this area. To address this, we have systematically assessed the areas of controversy, focusing on the inconsistencies in the evidence base. We used a PICOM strategy to search for relevant studies and the Newcastle–Ottawa Scale scoring to evaluate included publications. We reviewed the inconsistent clinical findings based on the relationship of Klotho with CKD stage, kidney and/or non-kidney adverse outcomes, and CKD-MBD in human studies. Subsequently, we assessed the underlying sources of the controversies and highlighted future directions to resolve these inconsistencies and clarify whether Klotho has a role as a biomarker in clinical practice in CKD.

5 May 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
SLSha-Sha Li
Sha-Sha Li
YLYan Liang
Yan Liang
JKJia-Wei Kong
Jia-Wei Kong
QZQi Zhang
Qi Zhang
JQJing-Rong Qian
Jing-Rong Qian
QLQi-Feng Liu
Qi-Feng Liu
Macrophage polarization and infiltration are notable characteristics of kidney injury and fibrosis. Although voltage-dependent potassium channel subtype (Kv) 1.3 is involved in macrophage-induced inflammation, its precise mechanism has not been elucidated. Therefore, this study aimed to explore the role of Kv1.3 in renal injury and macrophage polarization. Herein, mouse models of kidney injury were established through unilateral ureteral obstruction (UUO) and ischemia-reperfusion injury (IRI). For intervention, a selective Kv1.3 blocker, margatoxin (MgTx), was administered intraperitoneally. Blood and kidney samples were collected on days 3 and 7 following UUO surgery to evaluate renal Kv1.3 expression, kidney injury, macrophage polarization changes, cytokine levels, phosphorylation of extracellular signal-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B (NF-κB). Kidney samples were also collected 24 h after IRI to assess kidney injury and evaluate renal Kv1.3 expression, as well as the phosphorylation levels of ERK and NF-κB. Histological analysis of MgTx-treated UUO and IRI mice revealed that Kv1.3 inhibition markedly alleviated renal damage induced by UUO and IRI, substantially reducing the levels of myofibroblast markers, specifically α-smooth muscle actin and transforming growth factor-β1. In UUO mice, Kv1.3 expression and proportions of monocyte-derived cells in peripheral blood and M1 macrophages notably increased but reversed after MgTx treatment, indicating diminished macrophage infiltration. Additionally, MgTx treatment downregulated various M1-related proinflammatory markers, including tumor necrosis factor-α, inducible nitric oxide synthase, and interleukin (IL)-1β, and upregulated M2-associated markers such as IL-10, arginase-1, and CD206. Moreover, Kv1.3 overexpression in THP-1 cells upregulated M1 macrophage markers and proinflammatory cytokines, enhanced their migratory ability. This indicates an increased polarization towards the M1 phenotype, which correlates with impaired renal tubular epithelial cells. Notably, Kv1.3 upregulation both in vivo and in vitro led to increased phosphorylation of ERK and NF-κB, possibly promoting M1 macrophage polarization. This study establishes Kv1.3 as a pivotal regulator of renal fibrosis and macrophage polarization, showing that its inhibition leads to reduced infiltration and migration of M1 macrophages, mitigation of renal injury via suppression of ERK/NF-κB signaling. Altogether, these findings suggest the potential of Kv1.3 as a promising therapeutic target for renal fibrosis.

1 May 2025 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
YLYan Liang
Yan Liang
QZQi Zhang
Qi Zhang
JQJing-Rong Qian
Jing-Rong Qian
SLSha-Sha Li
Sha-Sha Li
QLQi-Feng Liu
Qi-Feng Liu
Chronic kidney disease (CKD) is influenced by inflammation, a critical factor in its progression. However, the underlying mechanism through which inflammation contributes to CKD is still obscure. The Klotho protein, which is predominantly found in the kidneys, is known for its protective functions, including anti-inflammatory, anti-aging, antioxidant, and anti-fibrotic effects. A myriad of studies have suggested that inflammation in CKD leads to a decrease in Klotho expression, diminishing Klotho protection capabilities and exacerbating kidney damage, thereby promoting CKD progression. These findings suggest that Klotho deficiency could be a crucial link between inflammation and CKD progression. However, the mechanism regarding their relationship is still unclear. The reduction in Klotho due to inflammation may be attributed to epigenetic mechanisms, such as DNA methylation, histone deacetylation, transcription factor, microRNA (miRNA) regulation and long non-coding RNA (lncRNA) regulation or non-epigenetic factors, such as endoplasmic reticulum (ER) stress and ER-associated degradation (ERAD), which affect Klotho protein metabolism. Through these pathways, inflammation triggers a decrease in Klotho expression, further driving CKD progression. Notably, Klotho also exerts a strong anti-inflammatory effect by inhibiting key inflammatory factors and pathways, suggesting that there is intricate crosstalk between inflammatory factors and Klotho in CKD. This review highlights how inflammation suppresses the expression of Klotho and further contributes to the development and exacerbation of CKD. By focusing on the interplay between inflammation and Klotho, the present review provides novel potential therapeutic strategies such as correcting epigenetic and non-epigenetic abnormalities for treating CKD by targeting this specific axis.

1 January 2023 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
LYLi Xia Yu
Li Xia Yu
MSMin Yue Sha
Min Yue Sha
YCYue Chen
Yue Chen
FTFang Tan
Fang Tan
XLXi Liu
Xi Liu
QLQi-Feng Liu
Qi-Feng Liu
Background: Diabetic kidney disease (DKD) is a serious diabetic complication and the performance of serum Klotho in DKD’s prognostic evaluation is controversial. Objective: To assess the association of serum Klotho with adverse kidney and non-kidney clinical outcomes in patients with DKD. Design: Clinical studies regarding the relationship of serum Klotho with DKD were included. Study quality was assessed using the Newcastle–Ottawa scale. Subgroup and sensitive analyses were performed to search for the source of heterogeneity. Data sources and methods: We comprehensively searched PubMed, Embase, Web of Science, and Cochrane library databases up to 27 September 2022. The associations of Klotho with albuminuria, such as the urinary albumin creatinine ratio (UACR), kidney outcomes such as persistent albuminuria, estimated glomerular filtration rate decline, and non-kidney outcomes such as diabetic retinopathy, cardiovascular morbidity, and mortality, were evaluated. The indicators, such as the correlation coefficient ( r), odds ratio (OR), relative risk, and hazard ratio, were retrieved or calculated from the eligible studies. Results: In all, 17 studies involving 5682 participants fulfilled the inclusion criteria and were included in this meta-analysis. There was no significant association of serum Klotho with UACR in DKD patients [summary r, −0.28 (−0.55, 0.04)] with high heterogeneity. By contrast, a strong association was observed regarding serum Klotho with kidney outcomes [pooled OR, 1.60 (1.15, 2.23)], non-kidney outcomes [pooled OR, 2.78 (2.11, 3.66)], or combined kidney and non-kidney outcomes [pooled OR, 1.96 (1.45, 2.65)] with moderate heterogeneity. Subgroup analysis indicated that age, study design, and the estimated glomerular filtration rate may be the sources of heterogeneity. Conclusion: A decreased serum Klotho level is possibly associated with an increased risk of developing kidney and non-kidney clinical outcomes in DKD patients; thus, Klotho may be a possible biomarker to predict DKD clinical outcomes. Additional studies are needed to clarify and validate Klotho’s prognostic value.